NMS – Real vaqt narxi. Valyuta: USD
290.10
-12.59 (-4.16%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
295.00
+4.90 (1.69%)
Bozordan keyin: Mar 27, 2026, 6:58 PM EDT
Praxis Precision Medicines, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda neyronlarning qo'zg'aluvchanlik-tormozlanish muvozanati bilan tavsiflangan markaziy asab tizimi (MAS) kasalliklari uchun terapiyalarni ishlab chiqish bilan shug'ullanadi. Kompaniyaning platformalari orasida Cerebrum, MAS uchun og'iz orqali qabul qilinadigan aniq terapiyalarni ishlab chiqish uchun kichik molekulalar platformasi; va antisense oligonukleotidlarini kashf qilish va ishlab chiqish uchun Solidus mavjud. Kompaniya, shuningdek, esensial tremorning davolash uchun NDA holatida bo'lgan T-tipli kaltsiy kanallarining kichik molekulali ingibitori bo'lgan ulixacaltamide; SCN2A va SCN8A rivojlanish va epilepsiya ensefalopatiyalarini (DEE) davolash uchun NDA holatida bo'lgan, shuningdek, keng DEE uchun 3-bosqich sinovida bo'lgan kichik molekula relutrigine; miyadagi natriy kanallarining giperfaol holatini maqsad qilib olgan, fokal epilepsiyani qo'shimcha davolash uchun 3-bosqich sinovida, shuningdek, fokal epilepsiyani monoterapiya uchun 2-bosqich sinovida bo'lgan kichik molekula vormatrigine; va SCN2A-DEEni davolash uchun 3-bosqich sinovida bo'lgan SCN2A gen ekspressiyasini tanlab kamaytirish uchun mo'ljallangan klinik bosqich ASO Elsunersenni ishlab chiqadi. Bundan tashqari, kompaniya preklinik sinovlarda PRAX-020ni KCNT1ni davolash uchun; PCDH19 mozaik ekspressiya kasalliklarini maqsad qilib olgan PRAX-080; SYNGAP1 funksiyasining yo'qolishini maqsad qilib olgan PRAX-090; va SCN2A LoF mutatsiyalarini maqsad qilib olgan PRAX-100ni o'z ichiga olgan mahsulot nomzodlarini ishlab chiqmoqda. Kompaniya RogCon Inc. bilan hamkorlik va litsenziyalash shartnomasiga; va Ionis Pharmaceuticals, Inc. bilan tadqiqot hamkorligi, opsion va litsenziyalash shartnomasiga ega. Kompaniya avval EpiPM Therapeutics, Inc. nomi bilan tanilgan va 2016 yil oktyabr oyida Praxis Precision Medicines, Inc. nomini o'zgartirgan. Praxis Precision Medicines, Inc. 2015 yilda ro'yxatdan o'tgan va shtab-kvartirasi Massachusets shtatining Boston shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Karl Hansen Ph.D. | Chief Technical Operations Officer |
| Dr. Orrin Devinsky M.D., Ph.D. | Head of Clinical Strategy |
| Dr. Steven Petrou B.Sc. (Hons.), Ph.D. | Co-Founder and President of Research & Development |
| Mr. Alex Nemiroff J.D. | General Counsel & Secretary |
| Mr. Brian Spar | Chief of Staff |
| Mr. Marcio Silva De'Souza M.B.A. | President, CEO & Director |
| Mr. Timothy Edwin Kelly | CFO & Treasurer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-08 | 8-K | prax-20260108.htm |
| 2026-01-07 | 8-K | tm261686d3_8k.htm |
| 2026-01-06 | 8-K | prax-20260106.htm |
| 2025-12-29 | 8-K | prax-20251229.htm |
| 2025-12-11 | 8-K | prax-20251209.htm |
| 2025-12-08 | 8-K | prax-20251204.htm |
| 2025-11-05 | 10-Q | prax-20250930.htm |
| 2025-10-21 | 8-K | prax-20251020.htm |
| 2025-08-04 | 8-K | prax-20250804.htm |
| 2025-07-17 | 8-K | prax-20250717.htm |
| Ms. Alyssa J. S. Wyant |
| Chief Regulatory & Quality Officer |
| Ms. Kelly McCue | Chief People Officer |
| Ms. Megan T. Sniecinski | Chief Operating Officer |